Linfangioleiomiomatose diagnosticada a partir de um pneumotórax espontâneo, um relato de caso
DOI:
https://doi.org/10.34117/bjdv9n1-071Keywords:
Lingangioleiomiomatose, pneumotórax, PneumologiaAbstract
A Linfagioleiomiomatose (LAM) é uma doença multissistêmica rara, caracterizada sobretudo por manifestações pulmonares. Sua apresentação inicial pode-se dar pelo desenvolvimento de Pneumotórax espontâneo, o qual ocorre em dois terços dos pacientes. A investigação diagnóstica deve ser realizada através de testes de função pulmonar, exames de imagem, bem como com a exclusão de doenças reumatológicas que participam do diagnóstico diferencial. O tratamento é a imunossupressão, sendo o Sirolimo considerado o padrão-ouro. Assim, o presente estudo tem como objetivos relatar um caso de Linfagioleiomiomatose diagnosticada partir do surgimento de um Pneumotórax espontâneo e revisar a literatura a respeito desta condição clínica.
References
AVILA, N.; KELLY, J.; CHU ET AL., S. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology, 2000. 216:147.
BALDI, B. et al. Assessment of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM). Lung, 2014. 192.
CHANG, W. et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Breathe Res, 2012.
CHU, S. et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest, 1999. 115:1041.
E, R. et al. Role of serum vascular endothelial growth factor D in discriminating patients with polycystic lung diseases.. Pol Arch Med Week, 2013. 123.
FRAZÃO ET AL, D. RELATO DE CASO –LINFANGIOLEIOMIOMATOSE PULMONAR E EXTRAPULMONAR. REVISTA SAÚDE E CIÊNCIA On line, 2015. 4(1): 6-11.
GUPTA, N. et al. Diagnosis and treatment of lymphangioleiomyomatosis: high-resolution chest computed tomography, transbronchial lung biopsy, and treatment of pleural disease. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med, 2017. 196.
HAGAMAN, J. et al. Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young nonsmoking women with spontaneous pneumothorax is cost-effective. Am J Respir Crit Care Med, 2010. 181:1376.
JOHNSON, S. et al. European Respiratory Society guidelines for the diagnosis and treatment of lymphangioleiomyomatosis. Eur Respir J, 2010. 35.
KALASSIAN, K.; DOYLE, R.; KAO, P. Lymphangioleiomyomatosis: new insights. Am J Respir Crit Care Med, 1997. 155:1183.
KITAICHI M, N. K. I. H. I. T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients, including a clinicopathological study of prognostic factors. Am J Respir Crit Care Med, 1995. 151:527.
LENOIR, S.; GRENIER, P.; BRAUNER ET AL., M. Pulmonary lymphangiomyomatosis and tuberous sclerosis: comparison of radiographic and tomographic findings in thin sections.. Radiology, 1990. 175:329.
LIMA, D. et al. Rev. Soc. Cardiol. Estado de Säo Paulo. Linfangioleiomiomatose: relato de caso, 2012. 15-18.
MATSUI, K.; TATSUGUCHI, A.; VALENCIA ET AL, J. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathological features in 22 cases. Hum Pathol, 2000. 31:1242.
MINISTÉRIO DA SAÚDE. Uso de Sirolimo em Linfangioleiomiomatose. Brasília – DF. 2020.
NATIONAL HEART, LUNG AND BLOOD INSTITUTE. NHLBI Workshop Summary. Workshop report on lymphangioleiomyomatosis. Am J Respir Crit Care Med, 1999. 159:679.
RYU, J. et al. Frequency of undiagnosed cystic lung disease in patients with sporadic renal angiomyolipomas. Chest, 2012. 141:163.
RYU, J.; MOSS, J.; BECK, G. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med, 2006. 173:105.
STEAGALL, W.; GLASGOW, C.; HATHAWAY ET AL., O. Genetic and morphological determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol , 2007. 293:L800.
TAYLOR, J. et al. Lymphangioleiomyomatosis. Clinical evolution in 32 patients. N Engl J Med, 1990. 323:1254.
YOUNG, L.; INOUE, Y.; MCCORMACK, F. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis.. N Engl J Med, 2008. 358.
